Trump’s 100% tariffs on generic drugs to reshape US pharma

President Donald Trump announced sweeping 100% tariffs on imported generic pharmaceutical drugs Tuesday, a move he says will force a dramatic reshaping of America’s drug manufacturing base. The tariffs are scheduled to take effect in August 2028, giving the industry roughly three years to adjust — though many executives warn that timeline is dangerously short.

What Trump actually said

Speaking at a White House event, Trump framed the tariffs as a matter of national security, arguing that the United States had become dangerously dependent on foreign-made drugs — particularly from India and China, which together supply the bulk of America’s generic medications. “We’re going to make our drugs here, in the USA,” Trump said. “We can’t be relying on other countries for our medicine.” The announcement builds on an executive order he signed earlier this year directing federal agencies to identify vulnerabilities in the pharmaceutical supply chain.

Generic drugs account for roughly 90% of all prescriptions filled in the United States, and the overwhelming majority of their active ingredients are manufactured abroad. That’s the core tension at the heart of Tuesday’s announcement.

Industry reaction is swift — and worried

The Association for Accessible Medicines, which represents generic drug manufacturers, pushed back hard. “A 100% tariff on generic medicines will not build factories overnight, but it will raise prices for patients immediately,” said David Gaugh, the group’s interim president. “We support domestic manufacturing, but this approach risks serious harm before a single new plant opens its doors.”

And that concern isn’t unfounded. Building a pharmaceutical-grade manufacturing facility in the US typically takes five to seven years and hundreds of millions of dollars. A 2028 deadline gives companies limited runway, and analysts at Goldman Sachs estimated Tuesday that the tariffs, if fully implemented, could raise the average cost of generic drug prescriptions by 25 to 40 percent.

The political calculus

Trump’s move is partly a response to bipartisan frustration over supply chain fragility exposed during the COVID-19 pandemic, when shortages of basic medications rattled hospitals across the country. Still, critics note that his first administration made similar promises about drug manufacturing without delivering lasting results. Democrats were quick to point out that higher generic drug prices would hit lower-income Americans hardest — exactly the constituency Trump claims to champion.

But the White House appears willing to absorb that political risk.

What happens next

The Commerce Department is expected to publish a formal rulemaking notice within 60 days, opening a public comment period. Several major drugmakers, including Teva and Mylan parent company Viatris, are already lobbying for exemptions or phased implementation. Congress could theoretically block the tariffs, but that seems unlikely given the current political dynamics on trade.

Whether the August 2028 deadline holds — or gets pushed, softened, or scrapped entirely under future political pressure — won’t be clear for some time. What’s certain is that the global generic drug industry just got a very loud warning shot.